Results 21 to 30 of about 260,154 (263)

Diagnostic and Therapeutic Pathway in Diffuse Malignant Peritoneal Mesothelioma

Cancers, 2023
Simple Summary Mesothelioma is a rare cancer that originates in mesothelial surfaces of the peritoneum, pleura, and other sites. Diffuse malignant peritoneal mesothelioma (DMPM) corresponds to approximately 15% of all mesotheliomas. Cytoreductive surgery
S. Kusamura, D. Baratti, M. De Simone, E. Pasqual, L. Ansaloni, D. Marrelli, M. Robella, F. Accarpio, M. Valle, S. Scaringi, D. Biacchi, Carmen Palopoli, S. Gazzanelli, M. Guaglio, M. Deraco   +14 more
semanticscholar   +1 more source

Diffuse malignant peritoneal mesothelioma: A review

Frontiers in Surgery, 2023
Diffuse malignant peritoneal mesothelioma (DMPM) is an unusual and life-threatening locally invasive tumor. The morbidity and mortality of the disease are associated with progressive local effects in the abdominal cavity, such as abdominal distention ...
Lu-Kun Sun, Chenguang Li, Shuohui Gao
semanticscholar   +1 more source

Genomic and transcriptomic analyses identify a prognostic gene signature and predict response to therapy in pleural and peritoneal mesothelioma

Cell Reports Medicine, 2023
Summary Malignant mesothelioma is an aggressive cancer with limited treatment options and poor prognosis. A better understanding of mesothelioma genomics and transcriptomics could advance therapies.
N. Nair, Q. Jiang, Jun S. Wei, V. Misra, B. Morrow, C. Kesserwan, Leandro C. Hermida, J. S. Lee, Idrees Mian, Jingli Zhang, A. Lebensohn, M. Miettinen, M. Sengupta, Javed Khan, E. Ruppin, R. Hassan   +15 more
semanticscholar   +1 more source

Principles of Surgical Management of Peritoneal Mesothelioma.

The Journal of the National Comprehensive Cancer Network, 2023
Malignant peritoneal mesothelioma (MPeM) is a rare malignancy and represents 5% to 30% of malignant mesothelioma cases. The primary curative therapy for MPeM is radical cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC ...
Jessica A. Steadman, T. Grotz
semanticscholar   +1 more source

Unusually Aggressive Presentation of Malignant Peritoneal Mesothelioma: Two Case Reports [PDF]

, 2022
Malignant peritoneal mesothelioma is a rare disease. Patients mainly present with abdominal distension, pain, nausea, and weight loss with or without an exposure history of asbestos.
Dominik Neff, Hannah Dietze, Dietze, Hannah, Joachim Müller, Früh, Martin, Padberg Sgier, Barbara-Christina, Martin Früh, Barbara-Christina Padberg Sgier, Müller, Joachim, Neff, Dominik   +9 more
core   +1 more source

Immunotherapy in malignant peritoneal mesothelioma (Review).

Molecular and clinical oncology, 2023
Over the last decade, there has been a movement in cancer treatment away from cytotoxic therapies toward strategies that enhance the immune system against cancer.
Sabah Alaklabi, A. Roy, J. Skitzki, R. Iyer   +3 more
semanticscholar   +1 more source

Contemporary Trends in Malignant Peritoneal Mesothelioma: Incidence and Survival in the United States

Cancers, 2022
Simple Summary This contemporary epidemiological analysis revealed a stable overall incidence of malignant peritoneal mesothelioma (MPM), but improved recognition of epithelioid histology.
L. Calthorpe, Fernanda Romero-Hernandez, Phoebe N Miller, Patricia C. Conroy, K. Hirose, A. Kim, K. Kirkwood, E. Nakakura, C. Corvera, A. Maker, A. Alseidi, M. Adam   +11 more
semanticscholar   +1 more source

Incidence, Survival Analysis and Future Perspective of Primary Peritoneal Mesothelioma (PPM): A Population-Based Study from SEER Database

Cancers, 2022
Simple Summary Mesotheliomas arising from the lining of the mesothelial cells of the peritoneum are rare. However, they are strongly linked to asbestos exposure, similar to the relatively well-known pleural mesotheliomas.
Asad Ullah, A. Waheed, J. Khan, Ankita Mishra, B. Tareen, Noor Nama, N. Karki, M. S. Panezai, L. V. Zarate, Joseph White, F. Cason, Nathaniel Matolo, S. Misra, N. Karim   +13 more
semanticscholar   +1 more source

Efficacy, Safety and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma

Cancer Discovery, 2021
Malignant peritoneal mesothelioma (MPeM) is a rare but aggressive malignancy with limited treatment options. VEGF inhibition enhances efficacy of immune-checkpoint inhibitors by reworking the immunosuppressive tumor milieu.
K. Raghav, Suyu Liu, M. Overman, Anneleis F Willett, M. Knafl, Szu-Chin Fu, A. Malpica, Seema Prasad, R. Royal, C. Scally, P. Mansfield, I. Wistuba, A. Futreal, D. Maru, L. S. Solis Soto, E. P. Parra Cuentas, Honglei Chen, P. Villalobos, A. Verma, A. Mahvash, P. Hwu, P. Cortazar, E. McKenna, C. Yun, S. Dervin, K. Schulze, W. Darbonne, A. Morani, S. Kopetz, K. Fournier, S. Woodman, James C. Yao, G. Varadhachary, D. Halperin   +33 more
semanticscholar   +1 more source

Ultra-high drug loading improves nanoparticle efficacy against peritoneal mesothelioma.

Biomaterials, 2022
Peritoneal mesothelioma is an aggressive disease with a median survival of under three years, due to a lack of effective treatment options. Mesothelioma is traditionally considered a "chemoresistant" tumor; however, low intratumoral drug levels coupled ...
Robert C. Sabatelle, Rong Liu, Yin-Po Hung, Eric M Bressler, Eliza Neal, Andrew Martin, Iriny Ekladious, M. Grinstaff, Y. Colson   +8 more
semanticscholar   +1 more source